FSD Pharma Provides Corporate Update
TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Brain
cbdMD Unveils ATRx Labs Premium Mushroom Line at GNC, Expanding cbdMD’s Natural Wellness Solutions
Charlotte, North Carolina--(Newsfile Corp. - May 24, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company") is...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free...
MyndTec Announces License Agreement with University of Toronto for Neuroregeneration Technology
Mississauga, Ontario--(Newsfile Corp. - May 23, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a medical technology company...
IRLAB Strengthens its Liquidity by Drawing SEK 25 million on a Previously Secured Loan Facility
GOTHENBURG, SE / ACCESSWIRE / May 23, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 23, 2024 - IRLAB Therapeutics...
Brain Cancer Canada Awards an $80,000 research grant to the development of dual function therapies that harness the body’s own immune system to kill brain tumour cells in glioblastomas
TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce $80,000 research grant has been awarded...
Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings
Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on...
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed...
Hyperfine, Inc. to Present at the Jefferies Global Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared...
Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB
GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Today, on Wednesday May 22, 2024, IRLAB Therapeutics...
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation
Updates on ETC Marketing, Inc and Ownership of ITV-1 and IPFALLEN, TX / ACCESSWIRE / May 22, 2024 / Enzolytics,...
Hyperfine, Inc. Celebrates ASNR 2024
The 2024 ASNR Annual Meeting had a strong focus on Alzheimer’s disease care and growing excitement about ultra-low-field MRILAS VEGAS--(BUSINESS...
Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
- Serena Hung, M.D., and Jeffrey Young will support company’s continued progress, including two planned IND submissions in 2025 -BOSTON--(BUSINESS...
Halberd/Athena GTX Research Promises a Much Brighter Future
Walt Disney once said, "All our dreams can come true if we have the courage to pursue them".JACKSON CENTER, PA...
IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757
GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics...
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased...
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds...
IRLAB Broadcasts the Annual General Meeting Live
GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics...
The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment
The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) will create the largest open data platform for ALS research...
IRLAB Presents at ABGSC Investor Days
GOTHENBURG, SWEDEN / ACCESSWIRE / May 21, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 21, 2024 - IRLAB Therapeutics...